Quality Investor
MarketsPortfolioEvidenceTestedCompareWatchlistAbout 

ResMed Inc.

Rank #143Capital ReturnWatchlistCompare with other stocks

RSMDF · OTC · Healthcare

ResMed Inc. (RSMDF) — Rank #143 by gross profitability (GP/assets 0.38) · ROE 23.1% · Piotroski F-Score 7 / 9.

As-of 2026-10-30 · CIK 0000943819 · all metrics point-in-time as of the filing date.

About

ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally.

Show more

It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc.

was founded in 1989 and is headquartered in San Diego, California.

Industry
Medical Instruments & Supplies
Sector
Healthcare
State
DE
Filer Category
Large accelerated filer
Fiscal Year End
June 30
Website
resmed.com

Company Snapshot

P/E and reverse DCF are the primary valuation lenses at this stage.

Market Cap

$31.80B

P/E (annual)

—

P/S (annual)

5.6

P/B

4.8

P/OCF (annual)

17.6

Shareholder Yield

2.0%

Employees

11,370

Industry

Medical Instruments & Supplies

Exchange

OTC

12/12

Flags passed

RSMDF passes 12/12 quality flags

  • PASS
    Gross margin holding
  • PASS
    Dilution within 2%
  • PASS
    FCF not negative from investment
  • PASS
    Disclosure consistent
  • PASS
    Revenue not declining
  • PASS
    Operating margin holding
  • PASS
    Free cash flow intact
  • PASS
    Passes safety gate
  • PASS
    Balance sheet stable
  • PASS
    No competitive retreat
  • PASS
    SBC not compressing margin
  • PASS
    No valuation convergence

Strengths Revenue growth accelerating · Operating leverage expanding

A count of the 12 warning flags that could be evaluated. Unweighted: colour follows the worst flag.

Quality Profile

Profitability

1/1 pass
GP / assets
0.38
Return on equity
23.1%
Gross margin trend
PASS

Safety

1/1 pass
Balance-sheet safety
PASS
Debt / equity
0.36
Current ratio
3.10×
Net cash
$809.87M

Cash Flow

3/3 pass
Positive FCF
PASS
Cash-backed earnings
PASS
Accruals healthy
PASS
SBC / revenue
1.8%

Growth

2/2 pass
Revenue growth
9.9%
Piotroski F-Score
7 / 9
Share dilution
-0.9%

FCF yield, shareholder yield, and buyback activity are the primary reads at this stage.

Profitability

Does it make money well?

No warning flags · GP/assets 53rd percentile of 20 SIC 3841 peers

Gross profitability (GP / assets)

0.38

Primary signal (Novy-Marx).

53rd pctl of 20 SIC 3841 peers

Return on equity

23.1%

Gross margin

61.1%

37th pctl of 20 SIC 3841 peers

Revenue growth (YoY)

9.9%

Gross margin improving

Margin trend vs prior year.

PASS

Operating Leverage

2023202420252026
Revenue vs COGS
Revenue vs OpEx
Op. Income vs Revenue

Growth

Revenue CAGR (3Y)

10.2%

Revenue CAGR (5Y)

12.1%

Earnings CAGR (3Y)

19.3%

FCF CAGR (3Y)

42.2%

Cash Flow Health

Is the cash real?

No warning flags · FCF 8% above net income

Free cash flow

$1.65B

Operating cash flow minus capex.

Positive free cash flow

PASS

FCF vs net income

8.3%

(FCF − net income) ÷ |net income|. Positive: cash above earnings. Negative: below.

FCF not below net income

Fails when free cash flow is below net income (yellow flag).

PASS

Accruals healthy

Cash-backed earnings.

PASS

SBC / revenue

1.8%

Stock-based comp intensity.

Balance Sheet Strength

Can it survive a storm?

No warning flags · net cash $809.87M, F-Score 7/9

Balance-sheet safety

Composite anti-fragile check.

PASS

Debt / equity

0.36

5th of 19 SIC 3841 peers (best = lowest)

Current ratio

3.10×

63rd pctl of 20 SIC 3841 peers

Quick ratio

1.80×

Net cash

$809.87M

Cash & equivalents minus total debt.

Piotroski F-Score

7 / 9

Fundamental-strength score (0-9).

Valuation

Is the price reasonable?

No warning flags

Dividend safety

Composite score

4.2 / 5

Strong
Payout ratio
23.0%5/5 Strong
FCF coverage
4.72×5/5 Strong
Dividend growth streak
10 yr5/5 Strong
Balance-sheet health
D/E 0.36 · IC N/A2/5 Fair

Capital allocation quality

Composite score

4.0 / 5

Strong
Share count trend(net buybacks)
-0.9%3/5 Good
Buyback timing
N/AN/A
Dividend growth consistency
10 yr5/5 Strong
Net debt trajectory(deleveraging)
3.0%4/5 Strong

Lifecycle Phase History

20212026
Capital Return

Price History

RSMDF-9.6% · -2.0% CAGRSPY+84.2% · +12.9% CAGR

View full financial statements →

Source filings on SEC EDGAR: 10-K annual reports · 10-Q quarterly reports